(Q46011061)

18 December 2017

title

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. (English)

1 reference

18 December 2017

0 references

Jane Castelli-Haley

1

1 reference

18 December 2017

MerriKay A Oleen-Burkey

series ordinal

2

1 reference

18 December 2017

Maureen J Lage

series ordinal

3

1 reference

18 December 2017

Kenneth P Johnson

series ordinal

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

14 May 2009

1 reference

18 December 2017

published in

Advances in Therapy

1 reference

18 December 2017

volume

26

1 reference

18 December 2017

issue

5

1 reference

18 December 2017

page(s)

552-562

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1007/s12325-009-0028-3

exact match

0 references

cites work

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS12325-009-0028-3

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-009-0028-3

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-009-0028-3

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-009-0028-3

A comprehensive assessment of the cost of multiple sclerosis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-009-0028-3

10.1007/S12325-009-0028-3

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017